FDA Grants Breakthrough Therapy Designation to Merck’s Sacituzumab Tirumotecan for EGFR-Mutated NSCLC

Spur Therapeutics Unveils SPR301: A Novel Gene Therapy for GBA1-Linked Parkinson’s Disease

M | O | C Cancer Care & Research Centre Achieves CAR-T Therapy Milestone

Aptose Biosciences Collaborates with NCI to Advance Tuspetinib in Precision Medicine Trials for AML and MDS

Novartis and PTC Therapeutics Forge $2.9 Billion Partnership for Huntington’s Drug PTC518

HCG and Accenture Partner to Transform Cancer Care with Advanced AI

GE HealthCare to Acquire Full Ownership of Nihon Medi-Physics, Expanding Molecular Imaging Leadership in Asia

Strand Life Sciences Unveils CancerSpot for Early Cancer Detection

Allink Biotherapeutics Secures $42 Million in Series A Financing to Accelerate Development of Next-Generation Oncology and Immunology Therapies

Apollo Cancer Centres Launch India’s First Lunglife Screening Programme for Early Detection of Lung Cancer

Agilus Diagnostics Unveils Claudin 18.2 Test: A Breakthrough in Cancer Care

Leqembi® Launched in South Korea for Early Alzheimer’s Disease Treatment

QIAGEN Expands QIAstat-Dx Operations with New Facility in Barcelona

SunAct Cancer Institute Partners with Abgentil Biomedical to Revolutionize Cancer Treatment in India

Dr. Reddy’s Launches Toripalimab in India for Advanced Nasopharyngeal Carcinoma

Home
/
update
/
details

Dr. Reddy’s Launches Toripalimab in India for Advanced Nasopharyngeal Carcinoma

NextEdge Admin

28 Nov 2024

2 min 45 sec

Dr. Reddy’s Laboratories has launched Toripalimab, a next-generation PD-1 inhibitor, in India under the brand name Zytorvi. Toripalimab is approved for the treatment of adults with recurrent or metastatic nasopharyngeal carcinoma (RM-NPC). With this launch, India becomes the third country worldwide, after China and the United States, to access this innovative immuno-oncology drug.

Toripalimab is approved by leading global regulatory bodies, including the USFDA, EMA, and MHRA, for its efficacy in RM-NPC. It is indicated as a first-line treatment for metastatic or recurrent locally advanced NPC in combination with gemcitabine and cisplatin. Additionally, it is approved as monotherapy for patients with recurrent unresectable or metastatic NPC who experience disease progression after platinum-based chemotherapy.

Dr. Reddy’s obtained exclusive rights to develop and commercialize Toripalimab in India, South Africa, Brazil, and other regions through a 2023 licensing agreement with Shanghai Junshi Biosciences. The agreement also allows for potential expansion into markets such as Australia and New Zealand.

Nasopharyngeal carcinoma is a rare form of head and neck cancer with a poor prognosis in advanced stages. According to GLOBOCAN 2022, over 120,000 new NPC cases were diagnosed globally in 2022, with 6,519 cases reported in India, making it one of the top five countries in terms of disease burden.

M.V. Ramana, CEO of Branded Markets (India and Emerging Markets) at Dr. Reddy’s, emphasized the milestone, stating, “Toripalimab meets a significant unmet need for NPC patients in India, offering superior outcomes compared to the standard of care.”

Dr. Reddy’s Laboratories operates across global generics, pharmaceutical services, active ingredients (PSAI), and proprietary products, reinforcing its commitment to delivering innovative solutions for unmet medical needs.